Scarica l'app Stockscreener
0.3475
4.98%
0.0142
Precedente Chiudi:
$0.3333
Aprire:
$0.3339
Volume 24 ore:
128.69K
Relative Volume:
0.32
Capitalizzazione di mercato:
$22.27M
Reddito:
$1.22M
Utile/perdita netta:
$-14.15M
Rapporto P/E:
-1.6545
EPS:
-0.21
Flusso di cassa netto:
$-6.55M
1 W Prestazione:
-2.18%
1M Prestazione:
-12.50%
6M Prestazione:
-31.78%
1 anno Prestazione:
+14.35%
Intervallo 1D:
$0.3302
$0.3486
Intervallo di 1 settimana:
$0.33
$0.3606
Portata 52W:
$0.2501
$0.9099
IGC Pharma Inc Stock (IGC) Company Profile
Nome
IGC Pharma Inc
Settore
Industria
Telefono
301-983-0998
Indirizzo
4336 Montgomery Avenue, Bethesda, MD
Confronta IGC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| IGC | 0.346 | 22.27M | 1.22M | -14.15M | -6.55M | -0.21 |
| VRTX | 449.35 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 749.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.75 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.29 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.11 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
IGC Pharma Inc Borsa (IGC) Ultime notizie
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - WSIL TV
IGC Pharma Reports 42% Revenue Growth, Advances Multiple Alzheimer's Drug Candidates | IGC Stock News - StockTitan
IGC (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - AccessWire
IGC Pharma CEO Reveals AI-Driven Strategy in Alzheimer's and Weight Loss Drug Development | IGC Stock News - StockTitan
IGC Pharma (STU:IGS1) Asset Turnover : 0.03 (As of Jun. 2024) - GuruFocus.com
MD’s IGC Pharma enrolls patients in Phase 2 trial for Alzheimer’s dementia drug - Maryland Daily Record
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - AccessWire
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts - Seeking Alpha
A Guide To The Risks Of Investing In IGC Pharma Inc (IGC) - Knox Daily
Investor’s Delight: IGC Pharma Inc (IGC) Closes Strong at 0.37, Up 0.13 - The Dwinnex
Was IGC Pharma Inc (IGC)’s session last reading good? - US Post News
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting - MSN
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - Markets Insider
Financial Metrics Check: IGC Pharma Inc (IGC)’s Ratios for Trailing Twelve Months - The Dwinnex
A Look at IGC Pharma Inc (IGC) Shares in the Recent Past Indicates Growth - SETE News
IGC Pharma Inc’s latest rating changes from various analysts - Knox Daily
IGC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Is IGC Pharma Inc (AMEX:IGC) stock a better investment at this time? - US Post News
AvePoint Inc’s latest rating changes from various analysts - Knox Daily
IGC Pharma Inc (AMEX: IGC) Down -0.99% This Year: What Is Going To Happen Next - Stocks Register
IGC Pharma director James Moran buys $200k in company stock - Investing.com Australia
IGC Pharma director James Moran buys $200k in company stock By Investing.com - Investing.com South Africa
Ipca Labs shares hit lifetime high after Nomura raises target price - Business Standard
IPCA Labs shares hit fresh 52-week high as Nomura upgrades target price on strong growth plans - Moneycontrol
Ipca Labs Shares Hit Life High As Nomura Hikes Target Price - NDTV Profit
Nomura expects IPCA Labs shares to rally over 20% from current price, retains Buy call - Business Upturn
EC approves Iqirvo plus UDCA to treat primary biliary cholangitis - World Pharmaceutical Frontiers
IPCA Laboratories Looking to Consolidate US Generics Business; Shares Gain - EquityPandit
Ipca Laboratories to Consolidate US Generics Business; Shares Up 1% - Indiainfoline
Ipca Laboratories to consider consolidaton of US generics business - CNBCTV18
StockNews.com Upgrades ICL Group (NYSE:ICL) to Strong-Buy - MarketBeat
Ipsen’s Iqirvo approved in Europe - The Pharma Letter
ICL Group (NYSE:ICL) Hits New 12-Month Low at $3.80 - MarketBeat
Ipsen’s Iqirvo® (elafibranor) approved in the European - GlobeNewswire
Ratio Revelations: IGC Pharma Inc (IGC)’s Financial Metrics in the Spotlight - The Dwinnex
IGC-AD1 shows promise in Alzheimer's tau pathology treatment By Investing.com - Investing.com Canada
Short Interest in ICL Group Ltd (NYSE:ICL) Declines By 6.3% - MarketBeat
IGM Biosciences (NASDAQ:IGMS) Trading Down 4.1% on Insider Selling - Defense World
ICL Group (NYSE:ICL) Shares Gap Down to $4.19 - Defense World
IGC-AD1 shows promise in Alzheimer's tau pathology treatment - Investing.com
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment - Business Wire
The Daily Hit: September 4, 2024 - Green Market Report
IGC Pharma targets Alzheimer’s market with anti-amyloid drug candidate - Green Market Report
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease - Yahoo Finance
IGC Pharma (NYSEMKT:IGC) Given New $3.75 Price Target at Ascendiant Capital Markets - Defense World
FTC Solar, Inc. (NASDAQ:FTCI) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
The Analyst Verdict: IGC Pharma In The Eyes Of 4 Experts - Benzinga
Moderna, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring - Barron's
The 7 Best Stocks Under 50 Cents To Buy For October 2024! - The Stock Dork
IGC Announces Results of its 2024 Annual Stockholders Meeting - Business Wire
IGC Pharma Inc Azioni (IGC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):